Back to search results

FibroScan for Detecting Elevated Central Venous Pressure in Heart Failure

This study is looking at whether a non-invasive test called FibroScan can accurately detect high central venous pressure (CVP) in people with heart failure. CVP is a measure of pressure in the large veins near the heart. Currently, the best way to measure CVP is with a procedure called right-sided heart catheterization (RHC), which involves inserting a tube into a vein. FibroScan uses sound waves to measure liver stiffness, which might be linked to high CVP. You could join if you are 18 or older, have suspected or diagnosed heart failure, and are already scheduled for an RHC. The study will compare FibroScan results to RHC results to see how well FibroScan identifies high CVP. The study's status is unclear.

Study design
This is a global, multi-center study aiming to enroll 149 participants. It is designed to compare a non-invasive test to a standard invasive procedure.
What's involved
You would have a FibroScan examination, a right-sided heart catheterization, a transthoracic echocardiography, and blood samples taken on Day 0.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements for this study are taken at Day 0.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07222813

Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)

Not Yet Recruiting
NAAges 18+InterventionalDiagnostic
Echosens
~149 participants
Updated 2025-10-30 on ClinicalTrials.gov
What's tested:FibroScanRight-sided Heart CatheterizationTransthoracic echocardiographyBlood Sample Analysis

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of individuals with elevated CVP (>10 mm Hg) who are correctly identified by LSM (cutoff of 13.3 kPa) [Sensitivity]
Measured over at Day 0
+1 more outcome measured

Conditions

Heart Failure
Heart Failure - NYHA II - IV

Explore related trials

Heart Failure

NCT07222813

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou

    Rennes, Ile Et Vilaine, Francestudy coordinator listed

  • Deutsches Herzzentrum der Charité (DHZC) - Klinik fuer Herz-, Thorax- und Gefaesschirurgie

    Berlin, Germanystudy coordinator listed

  • Keck Medicine of USC-Norris Healthcare Center - Transplant Clinic

    Los Angeles, Californiastudy coordinator listed

  • Medical University of South Carolina

    Charleston, South Carolinastudy coordinator listed

  • University of Minnesota

    Minneota, Minnesotastudy coordinator listed

  • University of Texas Southwestern Medical Center - Clinical Heart and Vascular Center - West Campus Building 3 Location

    Dallas, Texasstudy coordinator listed

  • Uniwersytet Medyczny im. Piastow Slaskich we Wroclawiu, Instytut Chorob Serca

    Wroclaw, Basse-Silésie, Polandstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

CAROLE MEILLEROUX, PharmD
[email protected]
+33622649277
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Proportion of individuals with elevated CVP (>10 mm Hg) who are correctly identified by LSM (cutoff of 13.3 kPa) [Sensitivity]at Day 0

    Sensitivity (true positive rate) = TP / (TP + FN)

  • Proportion of individuals without elevated CVP (>10 mm Hg) who are correctly identified by LSM (cutoff of 13.3 kPa) [Specificity]at Day 0

    Specificity (1 - false negative rate) = TN / (TN + FP)